Brian Rabinovich

Chief Scientific Officer

Dr. Brian Rabinovich is a founder and CSO of Fuse Biotherapeutics where he utilizes his experience as an Immunologist and expert in T cell and NK cell biology to direct the development of FuseBio’s pipeline of cis-acting immune and tumor-targeted cytokines. Prior to FuseBio, Brian was the Director of Redirected Immunotherapy and Head of NK cell Innovation at Merck KGaA where he led discovery projects developing multispecific fusion proteins that bridge immune cells to tumors and thereby redirect their specificity towards cancer. Brian also helped build Iovance from the ground up and spent over 15 years developing protein- and cell-based therapeutics at MD Anderson Cancer Center, Amgen, and Immunex. Brian earned his PhD in Immunology from the University of Toronto.

Talks About
#molecularbiology #cellculture

Preferred Locations
#NorthAmerica